Now today that 200 Day so far was the support, that is EXACTLY where the profit-taking stopped today.
So this definitely (so far) looks like a legitimate break-out.
When resistance level turns to support level....that is a very bullish sign.
And it is breaking out with good volume/price.
This is looking very good.
Which reduces attacks by 50 pct. with up to 12 injections, RBC's Michael Yee says"
What does that mean ?
It is so effective that no three stages required ?
Plus the FDA giving fast track , so maybe Cowen & Co. is right.
Please folks don't be too hard on tpstrong21, in school, fourth grade was the best three years of his life, since then it's been tough sledding.
You could be right, if they had a CC they would be in a situation that a question might come up that they would not want to discuss. Like a buy-out.
"All FDA approved IV iron products for the treatment of iron deficiency anemia are iron-carbohydrate complexes, and it is the carbohydrate moiety that triggers the anaphylactoid or hypersensitivity reactions, Dr. Gupta said. SFP (= soluble ferric pyrophosphate = Triferic) does not contain carbohydrate, he said, pointing out that not a single anaphylactoid reaction has occurred in patients being given SFP, even after approximately 60,000 human doses administered in clinical trials. With IV iron products, these anaphylactoid reactions do occur, and in one called ferumoxytol (=Feraheme), patients have to remain under observation for at least 30 minutes after administration, leading to significant inconvenience and restrictions as to where the drug can be given."
Yesterday's news is the kill shot: Approval and imminent launch of Rockwell Medical's Triferic - a highly differentiated and disruptive new entry into the CKD market. Many analysts expect Triferic to quickly change the treatment paradigm of iron replacement therapy in dialysis patients. That's due to the unique method of administration of Triferic which is the only iron replacement therapy which can be delivered via the dialysate solution. This creates the potential for dialysis providers to realize significant savings in nursing time and syringes and supplies associated with the separate - and now no longer necessary - administration of IV iron. Health benefits also accompany the use of Triferic since it is slowly infused into the blood from the dialysate during dialysis in a manner which closely resembles the absorption of dietary iron. Data from two large Phase III clinical trials (Cruise-1 and Cruise-2, which enrolled a total of ~600 patients) demonstrated statistically significant achievement of the primary and key secondary endpoints (all relating to important hemoglobin levels) in both trials as well as an excellent safety profile which was comparable to placebo.
A key motivator in the rapid adoption of Triferic will be its impact on reducing the usage of expensive erythropoiesis stimulating agents (ESAs, for example Amgen's EPO) by ~30-37% as demonstrated in a phase II trial. This translates in about $2,000 savings per patient per year. Although FDA did not allow an "ESA sparing claim" in the Triferic label (ODAC wanted a larger trial population), dialysis clinics are among the most economically savvy providers and will track the reduction in ESA usage and associated savings in real time and mandate Triferic uptake.
Rockwell Medical may be a relatively small company, but it has a strong balance sheet and a laser-like focus on CKD with a ~$50 MM revenue business in dialysis solutions. More importantly, it has strong relationships with leading dialysis providers such as DaVita and also executed a distribution agreement with industry leader Baxter in October 2014. That relationship is currently limited to hemodialysis concentrates, but it would be entirely logical to amend it to also cover Triferic. In the meantime, Rockwell won't be shy about promoting Triferic's important features versus Feraheme as AJ Gupta, MD and Chief Scientific Officer of Rockwell recently highlighted in a medical journal:
All FDA approved IV iron products
I wonder how that BoZo lindabakker gets to post all her twitter links ? Look at her messages, she posts twitter links all over the place.
How does yahoo pick and choose what links can be posted?
Haha...I'm a moron ?
Did they tell you that on..........TWITTER.......goofball ?
Hey lindabakker, you sound like a real pro...............but you gotta go someplace else for your stock tips other than........TWITTER !
Takes all kinds I guess.
All the names in the heading were associated in the past, and some still are in the present.
Everybody knows about Ivan Boesky and Michael Milken, or at least SHOULD know of them.
With very minimal research you can see what these #$%$ are, INCLUDING Jim Cramer, and his buddy Jonathon Aschoff (Brean Capital).
It helps to be aware of the wolves in sheepskin.